Our groundbreaking discovery suggests that targeting the TRIM29-PERK axis could serve as a potent therapeutic strategy not only for viral myocarditis but also for other infectious diseases linked to PERK. The gene discussed is EIF2AK3; the disease is viral myocarditis.